Literature DB >> 21526425

A case of metaplastic breast cancer that showed a good response to platinum-based preoperative chemotherapy.

Haruko Takuwa1, Takayuki Ueno, Hiroshi Ishiguro, Yoshiki Mikami, Shotaro Kanao, Masahiro Takada, Tomoharu Sugie, Masakazu Toi.   

Abstract

Patients with metaplastic breast cancer (MBC) exhibit reduced response to chemotherapy and have poor prognosis. We investigated a case of MBC that showed a positive response to preoperative chemotherapy, resulting in near pathological complete response (pCR). A 59-year-old woman complained of a lump in her right breast. Magnetic resonance imaging (MRI) showed the presence of a solid mass that was 24 mm in diameter. The pathological diagnosis was MBC with cartilaginous differentiation. The clinical stage was T2N0M0, stage IIA according to the International Union against Cancer (UICC) criteria. To observe the response to chemotherapy, we gave her preoperative chemotherapy. The patient was monitored closely, since we realized that failure of chemotherapy carries a risk of tumor progression. Evaluation was carried out using ultrasound, MRI, fluorodeoxyglucose (FDG) positron emission tomography (PET), and a Ki-67 labeling index after the first cycle of chemotherapy, and ultrasound after each additional cycle. FDG-PET showed a positive response after the first cycle of chemotherapy. The patient underwent 4 cycles of docetaxel (75 mg/m(2)) and cisplatin (75 mg/m(2)) followed by 4 cycles of cyclophosphamide (500 mg/m(2)), doxorubicin (50 mg/m(2)), and cisplatin (50 mg/m(2)). Ultrasound showed decreases in tumor size after each cycle of chemotherapy. After chemotherapy, MRI showed nearly complete regression of the tumor. Partial mastectomy was performed. Pathological examination showed few cancer cells remaining, indicating near pCR. We report a case of MBC that responded well to platinum-based preoperative chemotherapy. We propose that preoperative chemotherapy may be an option for treatment of MBC in conjunction with careful monitoring.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21526425     DOI: 10.1007/s12282-011-0269-2

Source DB:  PubMed          Journal:  Breast Cancer        ISSN: 1340-6868            Impact factor:   4.239


  7 in total

1.  Metaplastic breast cancer with chondrosarcomatous differentiation combined with concurrent bilateral breast cancer: A case report.

Authors:  Si-Yuan Yang; Yang Li; Jian-Yun Nie; Shou-Tao Yang; Xiao-Juan Yang; Mao-Hua Wang; Ji Zhang
Journal:  World J Clin Cases       Date:  2022-05-26       Impact factor: 1.534

2.  Metaplastic Carcinoma Breast: A Clinical Analysis of Nine Cases.

Authors:  Manashi Ghosh; A Muneer; Vinita Trivedi; Kaustav Mandal; Santosh Shubham
Journal:  J Clin Diagn Res       Date:  2017-08-01

3.  Clinicopathological characteristics and prognosis of metaplastic carcinoma of the breast.

Authors:  Meng Xiao; Zhengjun Yang; Xiaochuan Tang; Lan Mu; Xuchen Cao; Xin Wang
Journal:  Oncol Lett       Date:  2017-06-16       Impact factor: 2.967

4.  Revisiting Metaplastic Carcinoma of Breast: An Emphasis on the Clinico-pathological and Immunohistochemical Variables Analyzed at a Tertiary Cancer Centre in South India.

Authors:  Geetha V Patil Okaly; C Akshatha; N Sandhya; Akina Prakash; M N Suma; Ashwini Nargund; Shankar Anand; C Ramachandra; Libin Babu Cherian
Journal:  Iran J Pathol       Date:  2021-08-12

5.  Mixed epithelial and mesenchymal metaplastic carcinoma (carcinosarcoma) of the breast: a case report.

Authors:  Yu Kang; Shu Kang; Qingchang Li; Xinyu Zheng
Journal:  Eur J Med Res       Date:  2014-03-13       Impact factor: 2.175

6.  Metaplastic breast carcinomas - analysis of prognostic factors in a case series.

Authors:  Elżbieta Nowara; Anna Drosik; Marzenna Samborska-Plewicka; Ewa Magdalena Nowara; Agata Stanek-Widera
Journal:  Contemp Oncol (Pozn)       Date:  2014-06-03

Review 7.  Synchronous metaplastic breast carcinoma and lung adenocarcinoma: a rare case and review of the literature.

Authors:  Rebecca Lane; Felicia Yan; Daniel Higgins; Gauri Agarwal
Journal:  BMJ Case Rep       Date:  2020-03-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.